Natixis against cancer

© A. Cheron – Gustave Roussy

Natixis supports Institut Gustave Roussy’s new cancer treatment approach: personalized medicine. Natixis is supporting three new research teams. The first team is already working on “Cell deaths and senescence” in relation to radiation therapy.

Natixis supports Institut Gustave Roussy1

The Institute is one of the leading cancer research centers in Europe. Natixis’ support will help attract new talents and advance research towards personalized cancer treatment.

Some patients find themselves at an impasse when standard treatment can no longer help them. Personalized therapy brings new hope. This new approach takes into account the patient’s own characteristics and the specifics of the cancer genome to adjust the treatment.

Three Natixis research teams

As part of its sponsorship activities, Natixis will support 3 research teams during the next three years.

The first one, headed by Jean-Luc Perfettini, started its works on “Cell deaths and senescence*”.

The objective of the team is to target cancer cells more accurately during radiation, therefore increasing the efficiency of radiation therapy and the patients’ comfort. More specifically, the team aims to determine how radiation causes cell death or senescence and how to make cancer cells more sensitive to radiation. Eventually, it would like to direct the cell elimination mechanisms so that healthy cells can destroy cancer cells.

As a result, the more intrusive treatment methods, such as surgery or chemotherapy could be avoided in many cases.

The 2 other teams will be selected in 2013.

*physiological aging process (in this particular instance, the aging of cells)


Natixis’ commitment is shared by its staff, who for three years has taken part in the Odysséa race. Registration fees are paid to Institut Gustave Roussy for breast cancer research. 


More efficient methods to fight cancer

According to the WHO (World Health Organization), the number of deaths due to cancer should reach 13.1 million in 2030 worldwide versus 7.6 million in 2008.

In France, the number of new cases has practically doubled in 25 years but at the same time the risk of dying of cancer dropped 25% (Source: l'Institut national de veille sanitaire (InVS))

Nowadays, the treatment of people with cancer has greatly improved: better prevention; earlier, more frequent and more specific detection; more precise diagnosis; finally, personalized treatments using one or several techniques (surgery, chemotherapy, radiation therapy and brachytherapy, immunotherapy, transplant). All these treatments are efficient against cancer and give new hope.


1 Institut Gustave Roussy is the leading cancer research center in Europe and the world’s no. 10 leader for personalized medicine.
The Institute’s work is based on therapy innovation, the development of personalized medicine, healthcare quality and safety, with the patient always at the heart of the care.